Articles: sepsis.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.
Knowledge and understanding of gram-negative sepsis have grown over the past 20 years, but the ability to treat severe sepsis successfully has not. ⋯ Despite adequate sample size and high enrollment of patients with confirmed gram-negative sepsis, E5 did not improve short-term survival. Current study rationale and designs should be carefully reviewed before further large-scale studies of patients with sepsis are conducted.
-
Critical care medicine · Mar 2000
Randomized Controlled Trial Multicenter Study Clinical TrialAn immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients.
To determine whether early enteral feeding in a septic intensive care unit (ICU) population, using a formula supplemented with arginine, mRNA, and omega-3 fatty acids from fish oil (Impact), improves clinical outcomes, when compared with a common use, high protein enteral feed without these nutrients. ⋯ Immune-enhancing enteral nutrition resulted in a significant reduction in the mortality rate and infection rate in septic patients admitted to the ICU. These reductions were greater for patients with less severe illness.
-
Critical care medicine · Mar 2000
Randomized Controlled Trial Multicenter Study Clinical TrialPhase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
To evaluate the safety and efficacy of the platelet-activating factor receptor antagonist BB-882 in the treatment of patients with sepsis. ⋯ Treatment of sepsis with the platelet-activating factor antagonist BB-882 offers no advantage over placebo on survival, hemodynamic status, respiratory function, or organ failure scores.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the Systemic Mediator Associated Response Test.
Clinically useful predictions of end-organ function and failure in severe sepsis may be possible through analyzing the interactions among demographics, physiologic parameters, standard laboratory tests, and circulating markers of inflammation. The present study evaluated the ability of such a methodology, the Systemic Mediator Associated Response Test (SMART), to predict the clinical course of septic surgery patients from a database of medical and surgical patients with severe sepsis and/or septic shock. ⋯ SMART multivariate models accurately predict pathophysiology, shock, and organ failure in individual septic surgical patients. These prognostications may facilitate early treatment of end-organ dysfunction in surgical sepsis.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis.
To determine whether therapy with intravenous immunoglobulin G (IVIG) would decrease mortality in neonatal sepsis. ⋯ In the sample studied therapy with IVIG did not reduce mortality in neonatal sepsis